BioCentury
ARTICLE | Clinical News

Aminex shows MYCN is a regulator of the polyamine pathway

February 7, 2019 6:52 PM UTC

Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable MYCN target.

Increased levels of MYCN (v-myc myelocytomatosis viral related oncogene neuroblastoma derived; NMYC) occur in 40-50% of high-risk neuroblastomas. According to Aminex, no compounds have been able to directly target MYCN...